Xcout Intel
Abilita Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Abilita Therapeutics among biotech companies — ranked by similarity to what Abilita Therapeutics actually does, not by market-cap band.
Subscribe to see Abilita Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Abilita Therapeutics
Abilita Therapeutics, Inc. is a privately held biotechnology company founded in 2014 and focused on redefining therapeutics. The company is headquartered in San Diego, California.
Abilita Therapeutics at a glance
Abilita Therapeutics is a biotech company headquartered in United States. Its most recent funding round, Series A, closed in February 2023. Xcout tracks 6 named people at Abilita Therapeutics, including Jim Schmidt (Chief Financial Officer).
Abilita Therapeutics leadership
- Jim SchmidtChief Financial Officer
- Matthew RitterChief Business Officer
- Arshan AmiriGeneral Counsel
- Mauro MileniFounder & Chief Executive Officer
- Christopher B. RothSenior Vice President, Research
- Daniel BradburyDirector of the Board
Abilita Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Abilita Therapeutics competitors
Ranked by semantic similarity — how close each company is to Abilita Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Adcentrx Therapeutics is a privately held biotechnology company founded in 2021 that focuses on accelerating advanced medical treatments. Its research headquarters are located in San Diego, California.
Biotechnology
Autobahn Therapeutics, Inc. is a privately held biopharmaceutical company with its corporate office and headquarters located in San Diego, California, focused on restoring hope for patients.
Biotechnology
Autobahn Therapeutics is a biotechnology company headquartered in San Diego, California, focused on developing restorative treatments in the medical sector.
Biotechnology
Ablytx is a biotechnology company headquartered in San Diego and Del Mar, California. The company pioneers a class of medicines designed to selectively remove disease-driving proteins from cell surfaces.
Life Science
Synthorx, Inc., founded in 2014, is a biotechnology company headquartered in La Jolla, California, that engineered expanded genetic alphabet technologies to discover and develop novel protein therapeutics.
Biotechnology
Protalys Therapeutics, Inc. is a private drug discovery and development company headquartered in San Diego, California, operating within the therapeutics and drug pipeline sector.
Life Sciences
Crystalys Therapeutics is a biotechnology research company headquartered in San Diego, California, dedicated to developing novel therapies to address significant unmet medical needs.
Biotechnology
Cellics Therapeutics, Inc. is a privately held biotechnology company headquartered in San Diego, California, developing novel therapeutic products.
Biotechnology
Khartis Therapeutics is a biotechnology company headquartered in San Diego, California, developing oral small molecule medicines for immunological and related treatments.
Biotechnology
Novoron Bioscience, Inc. is a San Diego-based biotechnology company developing novel therapeutics to address central nervous system and other conditions.
Life Sciences (Therapeutics)
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Similar biotech company
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Abilita Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Abilita Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →